Xantis Pharma acquires Russian pharmaceutical company Alsi Pharma

Xantis Pharma, has acquired Russian pharmaceutical manufacturer Alsi Pharma. Xantis was founded in 2015, by the investment firm Novator and experienced pharmaceutical executives, with the vision of building a fully integrated pharmaceutical company in the markets where it operates, which currently are in Russia, Ukraine, the CIS and Central and Eastern Europe.

The company’s collective portfolio focuses on cardiovascular, gastroenterology, central-nervous-system (CNS), men’s-health, pain, allergy, arthritis and over-the-counter (OTC) products. Alsi currently distributes its products to Russian wholesalers, but by becoming part of Xantis they gain access to a commercial platform reaching pharmacy chains and doctors and in the future the hospital tenders market. Their products will also be distributed in selected CIS market.  

The combined company employs 500 people. Xantis plans to bring Alsi’s manufacturing facility in Kirov to full capacity utilization and will consider further expansion of the facility in the future. 

Lars Ramneborn, CEO of Xantis Pharma, commented on the acquisition: “Our team has an impressive track record in building profitable market share in the region where we operate and we have strong aspirations for this combination. By joining forces with Alsi, we see an opportunity to enhance our position in Russia and neighbouring countries and lay a stronger foundation for future growth in the region.”